Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update
ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosing. ASC30...
ITALY, SIGEP WORLD, THE GLOBAL FOODSERVICE COMMUNITY'S LEADING SHOW, IS ABOUT TO START: 1,300 BRANDS
Trends, innovation, technologies and now also pizza at Italian Exhibition Group's 46th edition featuring sustainable sector initiatives in the name of internationality, at Rimini Expo Centre from 18th to 22nd January RIMINI, Italy, Jan. 14, 2025...
IBM Study: AI Spending Expected to Surge 52% Beyond IT Budgets as Retail Brands Embrace Enterprise-Wide Innovation
The report found that 81% of surveyed executives and 96% of their teams are already using AI to a moderate or significant extent Executives indicate they want to expand into more sophisticated AI use cases, such as integrated business planning where...